Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783541 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL4847623 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL9296386 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL6783772 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL17191527 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL1448453 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL1150829 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL2709081 | 1.00 | POLB (0.53) | POLBCYP1A2CYP3A4CYP2C19FKBP1A | |
| SCHEMBL21441908 | 0.91 | FKBP1A (0.47) | POLBFKBP1AKLK7CTSLABCB1 | |
| SCHEMBL21285649 | 0.91 | FKBP1A (0.47) | POLBFKBP1AKLK7CTSLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1660447-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660443-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | SCHERING CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005016876-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-5120859-A | Anticoagulants | GENENTECH, INC. (US) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | POLB 2031/4885CYP1A2 4233/4885CYP3A4 4677/4885 |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | POLB 2216/4885CYP1A2 4271/4885CYP3A4 4706/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | POLB 2216/4885CYP1A2 4271/4885CYP3A4 4706/4885 |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | BACE1, BACE2, PSEN1 | POLB 1261/4885CYP1A2 1450/4885CYP3A4 1059/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | POLB 2031/4885CYP1A2 4233/4885CYP3A4 4677/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | POLB 2031/4885CYP1A2 4233/4885CYP3A4 4677/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | POLB 2216/4885CYP1A2 4271/4885CYP3A4 4706/4885 |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | BACE1, BACE2, BCHE | POLB 1206/4885CYP1A2 1837/4885CYP3A4 2043/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | POLB 1886/4885CYP1A2 4289/4885CYP3A4 4700/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | POLB 2031/4885CYP1A2 4233/4885CYP3A4 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.